Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1

Conditions

Fallopian Tube Neoplasms 8Ovarian Neoplasms 6Neoplasm Metastasis 5Breast Neoplasms 5Prostatic Neoplasms 4Triple Negative Breast Neoplasms 3Glioma 3Endometrial Neoplasms 3Wilms Tumor 2Small Cell Lung Carcinoma 2Sarcoma 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Pancreatic Neoplasms 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Medulloblastoma 2Lymphoma, Non-Hodgkin 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Glioblastoma 2Ependymoma 2Cholangiocarcinoma 2Central Nervous System Neoplasms 2Xanthogranuloma, Juvenile 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Sarcoma, Ewing 1Recurrent Ovarian High Grade Serous Adenocarcinoma 1

Interventions

Specimen Handling 11Magnetic Resonance Spectroscopy 10pembrolizumab 4sacituzumab govitecan 3cabozantinib 3atezolizumab 3Taxes 3Paclitaxel 3Nivolumab 3Gemcitabine 3Biopsy 3eribulin 2erdafitinib 2Radiosurgery 2Platinum 2Ipilimumab 2Docetaxel 2Cisplatin 2Carboplatin 2CTLA-4 Antigen 21,2-diaminocyclohexaneplatinum II citrate 2veliparib 1tazemetostat 1sapanisertib 1olaparib 1enfortumab vedotin 1carotuximab 1Tomography, X-Ray Computed 1Suramin 1Panvac-VF 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Carcinoma, Transitional Cell × olaparib × Clear all
NCT02769962 2025-07-28

Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
45 enrolled 30 charts
GenitourinaryThoracic

Carcinoma, Transitional Cell, Lung Neoplasms, Prostatic Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡